Zyversa Therapeutics Inc. 2025年季度报告

FORM10-Q (Mark One) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes:☐No:☒ As of May 7, 2025, the number of shares outstanding of the registrant’s common stock, $0.0001par value per share, was4,773,456. ZYVERSA THERAPEUTICS, INC. PART I - FINANCIAL INFORMATION1Item 1. Financial Statements.1Condensed Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 20241Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2025 and 20242Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31,2025 and 20243Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 20244Notes to Unaudited Condensed Consolidated Financial Statements5ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.11ITEM 3. Quantitative and Qualitative Disclosures About Market Risk.16ITEM 4. Controls and Procedures.16PART II - OTHER INFORMATION17ITEM 1. Legal Proceedings.17ITEM 1A. Risk Factors.17ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.17ITEM 3. Defaults Upon Senior Securities.17ITEM 4. Mine Safety Disclosures.17ITEM 5. Other Information.17ITEM 6. Exhibits.18SIGNATURES19i ZYVERSA THERAPEUTICS, INC. For The Three Months Ended March 31, 2025 and 2024(Unaudited) ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Note 1 –Business Organization, Nature of Operations and Basis of Presentation Organization and Operations ZyVersa Therapeutics, Inc. (“ZyVersa” and the “Company”) is a clinical stage biopharmaceutical company leveraging proprietarytechnologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accountingprinciples generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they donot include all of the information and disclosures required by accounting principles generally accepted in the United States of Americafor annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normalrecurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements ofthe Company as of March 31, 2025 and for the three months ended March 31, 2025 and 2024. The results of operations for the three On April 25, 2024,the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”).Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into oneshare of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have beenadjusted retroactively, where applicable, to reflect the 2024 Reverse Split and adjustment of the conversion price or exercise price of Note 2 -Going Concern and Management’s Plans The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates therealization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial As of March 31, 2025, the Company had cash of approximately $1.6million and a working capital deficit of approximately $9.9million. During the three months ended March 31, 2025, the Company incurred a net loss of approximately $2.3million and used cash The Company has not y